Lonza – C&GT CDMO Deep Dive – Part 2

  • Public Equity
  • Healthcare
  • Europe


Former executive at Lonza Group AG


  • Salient developments in the C&GT (cell and gene therapy) manufacturing market, including outsourcing rate, manufacturing economics and supply chain pressures
  • Latest M&A, corporate strategy and CAPEX trends among key tier 1 C&GT CDMO (contract development and manufacturing organisation) incumbents
  • Lonza’s (VTX: LONN) C&GT business unit deep dive – benchmarking vs customer KPC (key purchasing criteria), capacity, cost base and technology analysis
  • Lonza C&GT profitability outlook – ability to improve the clinical vs commercial programme balance and achieve operational efficiencies and improved yields
  • Key synergies between Lonza’s Biosciences and C&GT CDMO divisions


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited